Paltusotine’s Phase 3 PATHFNDR-1 study enrollment complete and topline data expected in 3Q 2023Paltusotine’s Phase 3 PATHFNDR-2 study enrollment ongoing with topline data now expected in. | February 28, 2023
SAN DIEGO - March 14, 2022 - Crinetics Pharmaceuticals, Inc. , a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for. | March 14, 2022
Crinetics Pharmaceuticals Appoints Caren Deardorf to Board of Directors SAN DIEGO, March 14, 2022 Crinetics Pharmaceuticals, Inc. , a clinical stage pharmaceutical. | March 14, 2022